Institut für Ernährungswissenschaft
Refine
Has Fulltext
- no (11)
Year of publication
- 2015 (11) (remove)
Document Type
- Article (8)
- Conference Proceeding (2)
- Review (1)
Language
- English (11)
Is part of the Bibliography
- yes (11)
Keywords
- Endothelin (3)
- ADPKD (1)
- BMP4 (1)
- Chronic kidney disease (1)
- Diabetic cardiomyopathy (1)
- Diabetic nephropathy (1)
- Dipeptidyl peptidase-4 inhibition (1)
- ET-1 (1)
- ETA (1)
- ETB (1)
- Endothelial nitric oxide synthase (1)
- Fibrosis (1)
- Hypoxia (1)
- Inflammation (1)
- Mice (1)
- Nitric oxide (1)
- Pulmonary arterial hypertension (1)
- Relaxin (1)
- SU5416 (1)
- acute kidney injury (1)
- albuminuria (1)
- auditory neurons (1)
- chronic kidney disease (1)
- differentiation (1)
- glycaemic control (1)
- linagliptin (1)
- polycystic kidney disease (1)
- type 2 diabetes (1)
Institute
Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects with Renal Disease with LINAgliptin (MARLINA-T2D), a multicentre, multinational, randomized, double-blind, placebo-controlled, parallel-group, phase 3b clinical trial, aims to further define the potential renal effects of dipeptidyl peptidase-4 inhibition beyond glycaemic control. A total of 350 eligible individuals with inadequately controlled type 2 diabetes and evidence of renal disease are planned to be randomized in a 1:1 ratio to receive either linagliptin 5mg or placebo in addition to their stable glucose-lowering background therapy for 24weeks. Two predefined main endpoints will be tested in a hierarchical manner: (1) change from baseline in glycated haemoglobin and (2) time-weighted average of percentage change from baseline in urinary albumin-to-creatinine ratio. Both endpoints are sufficiently powered to test for superiority versus placebo after 24weeks with =0.05. MARLINA-T2D is the first of its class to prospectively explore both the glucose- and albuminuria-lowering potential of a dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes and evidence of renal disease.